A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease.

摘要: Summary Background and Aim  The outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but less often. Aim  To explore this concept, we formally compared the efficacy proton pump inhibitors (PPIs) pantoprazole esomeprazole using rates remission judged against separately. Methods  Five hundred eighty-two patients with erosive were randomized to for 4, 8, or 12 weeks either 40 mg daily. Symptom was validated ReQuest™-GI subscale. Results  Approximately 75% free symptoms had no oesophageal lesions after 4 weeks’ treatment, rising about 93% 96%, respectively, at 12 weeks. Complete were, however, lower these time points; approximately 60% 90%, respectively. PPIs similar efficacy. Conclusions  Endoscopically separately over-estimated benefits both drugs. In contrast, indicates that may be treated inadequately when given standard 4- 8-week treatment. We suggest reliable clinically relevant